Combined therapy for large liver cancer with limited spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments—bland transarterial embolization (bTAE), hepatic artery infusion chemotherapy (HAIC), and systemic therapy—for people with large liver cancers that have limited spread. It might be an option if you have a big tumor and your liver is still working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and have been diagnosed with liver cancer (HCC).
- Your largest tumor is at least 10 cm (size of a grapefruit) and the total tumor size is at least 15 cm.
- Cancer has limited spread to the portal vein (type I or II) or to other parts of the body (5 or fewer spots).
- Your liver function is fairly good (Child-Pugh class A or B) and you have no serious health issues like bleeding or fluid buildup.
- Your blood counts and kidney function are within safe ranges (check with your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for a specific type of aggressive liver cancer called infiltrative hepatocellular carcinoma (HCC). It combines targeted therapy (lenvatinib), immunotherapy (sintilimab), and a procedure that delivers chemotherapy directly to the liver (bTAE-HAIC). The goal is to see if this triple approach works better for people with large tumors or those that have spread to the portal vein.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
This trial combines a targeted drug and immunotherapy with procedures that deliver cancer-killing beads or chemotherapy directly to your liver tumor. It is designed for people with large, inoperable liver cancer that has spread into the main vein leading to the heart.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.